ArticleScientific reports2025
Network toxicology, transcriptomics, and cytotoxic validation reveal TDCPP-induced pterygium mechanisms.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pterygium, a common ocular surface disorder, is associated with environmental factors such as ultraviolet exposure and air pollution. Tris(1,3-dichloro-2-propyl) phosphate (TDCPP), a widely used organophosphate flame retardant, has been detected in environmental and biological samples, yet its role in pterygium pathogenesis remains unclear. This study employed an integrative approach combining network toxicology, transcriptome sequencing, and in vitro cytotoxicity assays to elucidate the molecular mechanisms linking TDCPP exposure to pterygium development. Bioinformatics analysis identified 273 TDCPP-related targets and 1,078 pterygium-associated genes, with 43 overlapping candidates. Weighted gene co-expression network analysis (WGCNA) revealed two key modules correlated with pterygium phenotypes, highlighting MMP3 as a central regulator. Molecular docking and dynamics simulations confirmed stable interactions between TDCPP and MMP3 (binding energy: -5.9 kcal/mol), supported by RMSD, RMSF, and hydrogen bonding analyses. In vitro experiments demonstrated that low-dose TDCPP (0.5 µM) upregulated MMP3 expression in immortalized human conjunctival fibroblasts, enhancing cell proliferation, while higher concentrations (50 µM) induced cytotoxicity. These findings suggest that TDCPP promotes pterygium pathogenesis via MMP3-mediated extracellular matrix remodeling and fibroblast proliferation. This study provides novel insights into the environmental etiology of pterygium and identifies MMP3 as a potential therapeutic target for TDCPP-associated ocular surface disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.